Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve

StephenW

Gut Liver. 2011 Dec;5(4):478-85. Epub 2011 Nov 21.
Source: http://www.ncbi.nlm.nih.gov/pubmed/22195247
Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve
chronic hepatitis B patients at 48 weeks.
Wang LC, Chen EQ, Zhu XF, Xiong
ZH, Liu L, Xu L, Lei XZ, Liu C, Tang H. SourceCenter of Infectious
Diseases, West China Hospital, Sichuan University, Chengdu, China.

Abstract
BACKGROUND/AIMS: To reveal possible factors predicting the effect of
adefovir dipivoxil (ADV) treatment on chronic hepatitis B (CHB) and
optimize the utilization of ADV. METHODS: In total, 168 treatment-naïve
CHB patients were enrolled, including 117 hepatitis B e antigen
(HBeAg)-positive patients and 51 HBeAg-negative patients who met the
inclusion criteria. All patients were treated with ADV 10 mg per day for 48
weeks. Multiple logistic regression analyses were used to investigate
baseline factors, and responses at weeks 12 and 24 were analyzed as
predictive values. RESULTS: Multiple regression analyses showed that
baseline HBeAg status and HBV DNA levels significantly affected the
virological response (VR) (p<0.05), baseline ALT levels were an independent
predictor of serological response (SR) (p<0.05) and the body mass index
(BMI) may affect the biochemical response (BR) (p<0.05). There was a
statistically significant difference in the VR and SR between patients with
a primary nonresponse (PNR) at week 12 and those with a VR at week 12
(p<0.01). Additionally, the VR was significantly different between patients
with HBV DNA lower than 10(3) copies/mL at week 24 and those with greater
than 10(3) copies/mL (p<0.01).
CONCLUSIONS: Patients with negative HBeAg,
lower HBV DNA levels and higher ALT values at baseline are more suitable
for ADV treatment, whereas patients with lower BMIs may be more amenable to
ALT normalization. Adjustments for treatment strategy should be considered
if PNR at week 12 or HBV DNA =10(3) copies/mL at week 24 is observed.

StephenW

肠肝。 2011月;5（4）:478- 85。 EPUB2011年11月21。
资料来源：http://www.ncbi.nlm.nih.gov/pubmed/22195247
预测治疗过阿德福韦酯的疗效的因素
慢性乙型肝炎患者在48周。
王立法会，陈均衡，朱啸风，雄
华，刘良，徐林，李征，刘，唐华SourceCenter传染病
疾病，中国西部医院，四川大学，成都，中国。

摘要
背景/目标：揭示预测的效果的可能因素
阿德福韦酯（ADV）治疗慢性乙型肝炎（CHB）
优化利用ADV。方法：总共168治疗初治
慢性乙肝患者入选，其中包括117 B型肝炎e抗原
（HBeAg）阳性的患者和51 HBeAg阴性患者符合
纳入标准。所有患者均采用ADV每天10毫克48
周。多因素Logistic回归分析被用来调查
基线因素，并在12周和24周的反应分析
预测值。结果：多元回归分析表明，
基线HBeAg的状态和HBV DNA水平显着影响
病毒学应答（VR）（P <0.05），基线ALT水平是一个独立的
预测的血清学反应（SR）（P <0.05）和身体质量指数
（BMI）的可能影响的生化反应（BR）（P <0.05）。有一个
在VR和SR与患者之间的的统计学上显著的差异
主无应答（PNR）在第12周，并在12周VR的
（P <0.01）。此外，VR患者之间的显着不同
HBV - DNA低于10（3）拷贝/毫升24周时，有更大的
（3）小于10拷贝/ ml（P <0.01）。
结论：HBeAg阴性患者，
降低HBV DNA水平和基线ALT值较高，更适合
ADV治疗，而与较低的BMI患者可能会更适合
ALT正常化。应考虑调整治疗策略
如果在12周或HBV - DNA=10（3）拷贝/毫升在24周的PNR是观察。